한글목차

세계의 바이오마커 시장 규모는 2025년 623억 9,000만 달러에서 2030년까지 1,041억 5,000만 달러에 이를 것으로 예측되며, 예측 기간 중 CAGR 10.8%의 성장이 예상됩니다.

시장 성장은 이러한 분석 키트가 표준화되고 최적화된 프로토콜을 제공함으로써 다양한 생물학적 샘플에서 바이오마커의 정확하고 효율적인 분석을 용이하게 하고 의료 진단 및 연구 활동에 크게 기여한다는 장점이 있습니다. 게다가 유전체학, 단백질체학, 메타보로믹스, 차세대 시퀀싱 등의 기술의 진보에 의해 바이오마커의 기능이 확대되고 있습니다.

"예측 바이오마커 부문은 2024년 효능 바이오마커 시장에서 가장 큰 점유율을 차지했습니다."

2024년 세계 바이오마커 시장에서는 예측 바이오마커 부문이 효능 바이오마커 부문에서 가장 큰 점유율을 차지했습니다. PATHWAY anti-HER2/neu(4B5) 검사는 trastuzumab deruxtecan(ENHERTU)의 투여 대상이 되는 HER2 저치 유방암 환자를 동정하는 것으로, 2025년 1월에 HR 양성, HER2 음성 전이성 유방암의 HER2 초저치 환자를 동정하도록 적응 확대되었습니다.

"면역측정법은 2024년 바이오마커 기술 시장에서 가장 큰 점유율을 차지했습니다."

2024년, 면역 측정법은 바이오마커 시장에서 가장 큰 시장 점유율을 차지했으며, 이는 특히 종양, 심장병 및 감염과 같은 다양한 질병 영역에 걸쳐 다양한 바이오마커를 검출할 수 있는 능력 때문입니다. 주요 기업은 진단 서비스를 강화하기 위해 면역 분석 플랫폼의 개발을 적극적으로 진행하고 있습니다. Roche는 암 검사용으로 Elecsys Anti-p53 immunoassay를 제공하고 Abbott는 감염성 검사 및 만성 질환 모니터링을 위해 회사의 ARCHITECT 및 Alinity immunoassay 시스템을 지속적으로 확장하고 있습니다.

"아시아태평양은 예측 기간 동안 바이오 마커 시장에서 가장 높은 CAGR로 성장할 것입니다."

아시아태평양은 예측기간 바이오마커 시장에서 최고의 성장률을 나타낼 것으로 예측됩니다. 이 성장의 주된 촉진요인은 선진의 의료 검사를 받는 환자 인구가 많은 것, 암 치료를 개량하기 위한 의료 정책이 지지되고 있는 것입니다. 게다가 새로운 약물 치료를 개발하기 위한 제약기업과 생명공학기업에 의한 연구활동의 활성화도 시장 확대를 가속시킬 것으로 예측됩니다. 지역 전체에서 의약품 개발에 대한 투자가 계속 증가하고 있기 때문에 창약 및 개발 활동을 지원하는 바이오마커 수요도 꾸준히 성장하고 있습니다.

이 보고서는 세계 바이오마커 시장에 대한 조사 분석을 통해 주요 촉진요인 및 억제요인, 경쟁 구도, 미래 동향 등의 정보를 제공합니다.

목차

제1장 서론

제2장 조사 방법

제3장 주요 요약

제4장 주요 조사 결과

• 바이오마커 시장 개요
• 아시아태평양의 바이오마커 시장 : 제공별
• 바이오마커 시장 점유율 : 최종 사용자별(2024년)
• 바이오마커 시장 : 지리적 성장 기회

제5장 시장 개요

• 소개
• 시장 역학
  • 시장 성장 촉진요인
  • 억제요인
  • 기회
  • 과제
• 고객의 비즈니스에 영향을 미치는 동향/혼란
• 규제 분석
  • 규제 시나리오
  • 규제기관, 정부기관, 기타 조직
• 밸류체인 분석
• 기술 분석
  • 주요 기술
  • 보완 기술
  • 인접 기술
• 가격 분석
  • 어세이 킷의 판매 가격의 동향 : 주요 기업별(2022-2024년)
  • 바이오마커 소모품 판매 가격 동향 :지역별(2024년)
• 특허 분석
  • 조사 방법
  • 특허출원건수 : 서류종별(2014-2025년)
• 생태계 분석
• 주요 컨퍼런스 및 이벤트(2025-2026년)
• Porter's Five Forces 분석
• 주요 이해관계자와 구매 기준
• 투자 및 자금조달 시나리오
• 무역 데이터 애널리틱스
  • 수입 시나리오 : HS코드 382200(2020-2024년)
  • 수출 시나리오 : HS코드 382200(2020-2024년)
• 바이오마커 시장에 대한 AI/생성형 AI의 영향
  • 소개
  • 이용 사례
  • 바이오마커 생태계에서 AI의 미래
• 바이오마커 시장에 대한 2025년 미국 관세의 영향
  • 주요 관세율
  • 가격의 영향 분석
  • 국가 및 지역에 대한 영향
  • 최종 이용 산업에 미치는 영향

제6장 바이오마커 시장 : 제공별

• 소개
• 소모품
  • 분석 키트
  • 시약 및 화학제품
  • 기타 소모품
• 서비스
• 소프트웨어

제7장 바이오마커 시장 : 유형별

• 소개
• 안전성 바이오마커
• 유효성 바이오마커
  • 예측 바이오마커
  • 사로 게이트 바이오마커
  • 약역학 바이오마커
  • 예후 바이오마커
• 검증 바이오마커

제8장 바이오마커 시장 : 연구 분야별

• 소개
• 유전체학
• 단백질체학
• 대사체학
• 기타 연구분야

제9장 바이오마커 시장 : 기술별

• 소개
• 면역 분석
  • ELISA
  • 단백질 마이크로어레이
  • 웨스턴 블로팅
• 차세대 시퀀싱(NGS)
• 중합효소 연쇄반응(PCR)
• 질량 분석
• 크로마토그래피
• 기타 기술

제10장 바이오마커 시장 : 적응 질환별

• 소개
• 암
• 감염증
• 면역 질환
• 신경질환
• 심혈관 질환
• 기타 적응 질환

제11장 바이오마커 시장 : 용도별

• 소개
• 임상 진단
• 창약 및 의약품 개발
• 맞춤형 의료
• 임상 연구
• 기타 용도

제12장 바이오마커 시장 : 최종 사용자별

• 소개
• 제약 및 바이오테크놀러지 기업
• 병원 및 진단실험실
• 학술기관 및 연구기관
• 기타 최종 사용자

제13장 바이오마커 시장 : 지역별

• 소개
• 북미
  • 북미의 거시경제 전망
  • 미국
  • 캐나다
• 유럽
  • 유럽의 거시 경제 전망
  • 독일
  • 영국
  • 프랑스
  • 이탈리아
  • 스페인
  • 기타 유럽
• 아시아태평양
  • 아시아태평양의 거시 경제 전망
  • 중국
  • 일본
  • 인도
  • 한국
  • 호주
  • 기타 아시아태평양
• 라틴아메리카
  • 라틴아메리카의 거시 경제 전망
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
• 중동
  • 중동의 거시 경제 전망
  • GCC 국가
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 GCC 국가
  • 기타 중동
• 아프리카

제14장 경쟁 구도

• 소개
• 주요 진입기업의 전략/강점
• 수익 분석(2022-2024년)
• 시장 점유율 분석(2024년)
• 기업 평가 매트릭스 : 주요 기업(2024년)
• 기업의 평가 매트릭스 : 스타트업/중소기업(2024년)
• 기업 평가 및 재무 지표
  • 주요 기업의 평가
  • 주요 기업의 재무 지표
• 브랜드/제품 비교 분석
• 경쟁 시나리오

제15장 기업 프로파일

• 주요 기업
  • THERMO FISHER SCIENTIFIC INC.
  • MERCK KGAA
  • F. HOFFMANN-LA ROCHE LTD.
  • QIAGEN
  • ABBOTT
  • AGILENT TECHNOLOGIES, INC.
  • REVVITY INC.
  • CHARLES RIVER LABORATORIES
  • BIO-RAD LABORATORIES, INC.
  • EUROFINS SCIENTIFIC
  • BIOMERIEUX
  • ILLUMINA, INC.
  • JSR CORPORATION
  • GUARDANT HEALTH
  • LABCORP
  • QUANTERIX
  • MESO SCALE DIAGNOSTICS, LLC
• 기타 기업
  • CELERION
  • STANDARD BIOTOOLS
  • SEBIA
  • BIOAGILYTIX LABS
  • STRESSMARQ BIOSCIENCES INC.
  • NORTHEAST BIOANALYTICAL LABORATORIES LLC
  • SIGNOSIS
  • SERIMMUNE
  • THERAINDX LIFESCIENCES PVT. LTD.
  • SYNEXA LIFE SCIENCES BV
  • DIATECH PHARMACOGENETICS
  • SINGULEX, INC.
  • R-BIOPHARM AG

제16장 부록

영문목차

The biomarkers market is expected to reach USD 104.15 billion in 2030 from USD 62.39 billion in 2025, at a CAGR of 10.8% during the forecast period. The growth of this market can be attributed to the advantage that these assay kits offer standardized and optimized protocols, facilitating accurate and efficient analysis of biomarkers in various biological samples, thus contributing significantly to diagnostic and research endeavors in healthcare. Further, advances in technologies such as genomics, proteomics, metabolomics, and next-generation sequencing have expanded the capabilities of biomarkers. This has led to the development of novel biomarkers with enhanced sensitivity, specificity, and predictive value.

"The predictive biomarkers segment accounted for the largest share of the efficacy biomarkers market in 2024."

The market by type is segmented into safety, efficacy, and validation biomarkers. Efficacy biomarkers are further segmented into predictive, surrogate, pharmacodynamic, and prognostic biomarkers. In 2024, the predictive biomarkers segment accounted for the largest share of the efficacy biomarkers segment in the global biomarkers market. This large share is supported by the ability of predictive biomarker-based offerings to guide treatment decisions and improve clinical outcomes by identifying patients most likely to benefit from a particular therapeutic intervention, which is especially valuable in oncology, autoimmune disorders, and infectious diseases. Moreover, the growing number of companion diagnostic approvals linked to predictive biomarkers further reinforced their adoption across healthcare settings. For instance, Roche's PATHWAY anti-HER2/neu (4B5) test identifies HER2-low breast cancer patients eligible for trastuzumab deruxtecan (ENHERTU), which received a label expansion in January 2025 to identify HER2-ultralow patients in HR-positive, HER2-negative metastatic breast cancer.

"Immunoassays held the largest share in the biomarker technologies market in 2024."

The biomarkers market is segmented by technology into immunoassays, NGS, PCR, mass spectrometry, chromatography, and other technologies. In 2024, immunoassays held the largest market share in the biomarkers market due to their high specificity and ability to detect various biomarkers across various disease areas, particularly in oncology, cardiology, and infectious diseases. Scalability and automation capabilities further support high-throughput testing, meeting the rising demand for precision diagnostics. Major companies are actively advancing immunoassay platforms to enhance their diagnostic offerings. For instance, Roche offers the Elecsys Anti-p53 immunoassay for cancer diagnostics, while Abbott continues to expand its ARCHITECT and Alinity immunoassay systems for infectious disease testing and chronic condition monitoring.

"The Asia Pacific region is growing at the highest CAGR in the biomarkers market during the forecast period."

The Asia Pacific is projected to register the highest growth rate in the biomarkers market during the forecast period. Key drivers of this growth include a large patient population undergoing advanced medical testing and supportive healthcare policies to improve cancer care. Additionally, increased research activity by pharmaceutical and biotechnology companies to develop novel drug therapies is expected to accelerate market expansion. As investment in drug development continues to rise across the region, the demand for biomarkers that support drug discovery and development efforts is growing steadily.

The primary interviews conducted for this report can be categorized as follows:

• By Company Type: Tier 1- 44%, Tier 2- 32%, and Tier 3- 24%
• By Designation: (Managers)- 45%, (CXOs, Directors)- 30%, and (Executives)- 25%
• By Region: North America- 40%, Europe- 25%, Asia Pacific- 20%, Rest of the World- 15%

F. Hoffmann-La Roche Ltd (Switzerland), Merck KGaA (Germany), Thermo Fisher Scientific Inc. (US), Abbott (US), QIAGEN (Netherlands), Revvity (US), and Laboratory Corporation of America Holdings (US) are some of the key players in the biomarkers market.

The study includes an in-depth competitive analysis of these key players in the biomarkers market, with their company profiles, recent developments, and key market strategies.

Research Coverage:

This research report categorizes the biomarkers market by offering [consumables (assay kits, columns & filters, reagents & chemicals), services, and software], type (safety biomarkers, efficacy biomarkers (surrogate biomarkers, pharmacodynamics biomarkers, predictive biomarkers, and prognostic biomarkers), and validation biomarkers), research area (genomics, proteomics, metabolomics, and other research area), technology [immunoassays (western blot, ELISA, and protein microarray), NGS, PCR, mass spectrometry, chromatography, and other technologies], disease indication (cancer, infectious diseases, cardiovascular disorders, immunological disorders, neurological disorders, and other disease indications), application (clinical diagnostics, drug discovery & development, personalized medicines, clinical research, and other applications), end user (pharmaceutical & biotechnologies companies, hospitals & diagnostics laboratories, research & academic institutes, and other end users), and region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa).

The report provides in-depth information on significant factors influencing the growth of the biomarkers market, including drivers, trends, challenges, and opportunities. A thorough analysis of major industry players has been undertaken to provide insights into their business profiles, products/services, key strategies, collaborations, partnerships, and agreements. Additionally, the report encompasses recent developments such as new product launches and acquisitions within the biomarkers market.

Key Benefits of Buying the Report:

The report will help market leaders and new entrants by providing the closest approximations of the revenue numbers for the overall biomarkers market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their businesses and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

• Analysis of key drivers (increasing use of biomarkers in drug discovery & development, growing importance of companion diagnostics, rising prevalence of cancer, developments of biomarkers for rare diseases, increasing funds and grants for biomarker research, advancement in omics technologies), restraints (high capital investments and extensive timelines for biomarker development, disease complexity, and heterogeneity), opportunities (growing preference for personalized medicine and precision oncology, enhanced collaboration among healthcare providers and key industry players, high growth potential of emerging economies), and challenges (issues associated with quantification and validation of biomarkers, complexities associated with data set integration, technical issues related to sample collection and storage) influencing the growth of the market.
• Product Development/Innovation: Detailed insights on newly launched products/services of the biomarkers market
• Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
• Market Diversification: Exhaustive information about new products/services, untapped geographies, recent developments, and investments in the biomarkers market
• Competitive Assessment: In-depth assessment of market share, growth strategies and service offerings of leading players like F. Hoffmann-La Roche Ltd (Switzerland), Merck KGaA (Germany), Thermo Fisher Scientific Inc. (US), Abbott (US), QIAGEN (Netherlands), Revvity (US), Laboratory Corporation of America Holdings (US), Charles River Laboratories (US), Bio-Rad Laboratories, Inc. (US), Eurofins Scientific (Luxembourg), BIOMERIEUX (France), Agilent Technologies, Inc. (US), JSR Corporation (Japan), and Quanterix (US), among others, in the biomarkers market.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
  • 1.2.1 INCLUSIONS & EXCLUSIONS
• 1.3 STUDY SCOPE
  • 1.3.1 STUDY SCOPE
• 1.4 YEARS CONSIDERED
• 1.5 CURRENCY CONSIDERED
• 1.6 STAKEHOLDERS
• 1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
  • 2.1.2 PRIMARY DATA
• 2.2 MARKET ESTIMATION METHODOLOGY
  • 2.2.1 INSIGHTS OF PRIMARY EXPERTS
  • 2.2.2 TOP-DOWN APPROACH
• 2.3 MARKET GROWTH RATE FORECAST
• 2.4 MARKET BREAKDOWN & DATA TRIANGULATION
• 2.5 RESEARCH ASSUMPTIONS
• 2.6 RESEARCH LIMITATIONS
• 2.7 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 BIOMARKERS MARKET OVERVIEW
• 4.2 ASIA PACIFIC: BIOMARKERS MARKET, BY OFFERING
• 4.3 BIOMARKERS MARKET SHARE, BY END USER, 2024
• 4.4 BIOMARKERS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 MARKET DRIVERS
    • 5.2.1.1 Increasing use of biomarkers in drug discovery & development
    • 5.2.1.2 Growing importance of companion diagnostics
    • 5.2.1.3 Rising prevalence of cancer
    • 5.2.1.4 Development of biomarkers for rare diseases
    • 5.2.1.5 Increasing funds and grants for biomarker research
    • 5.2.1.6 Advancement in omics technologies
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 High capital investments and extensive timelines for biomarker development
    • 5.2.2.2 Disease complexity and heterogeneity
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Growing preference for personalized medicine and precision oncology
    • 5.2.3.2 Enhanced collaboration among healthcare providers and key industry players
    • 5.2.3.3 High growth potential of emerging economies
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Issues associated with quantification & validation of biomarkers
    • 5.2.4.2 Complexities associated with data set integration
    • 5.2.4.3 Technical issues related to sample collection and storage
• 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.4 REGULATORY ANALYSIS
  • 5.4.1 REGULATORY SCENARIO
    • 5.4.1.1 US
    • 5.4.1.2 Europe
    • 5.4.1.3 Asia Pacific
    • 5.4.1.4 Rest of the World
  • 5.4.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.5 VALUE CHAIN ANALYSIS
• 5.6 TECHNOLOGICAL ANALYSIS
  • 5.6.1 KEY TECHNOLOGIES
    • 5.6.1.1 Immunoassays
      • 5.6.1.1.1 Immunohistochemistry (IHC)
      • 5.6.1.1.2 ELISA
    • 5.6.1.2 Next-generation Sequencing (NGS)
    • 5.6.1.3 Polymerase chain reaction (PCR)
    • 5.6.1.4 In situ hybridization
    • 5.6.1.5 Microarrays
    • 5.6.1.6 Mass Spectrometry
  • 5.6.2 COMPLEMENTARY TECHNOLOGIES
    • 5.6.2.1 Liquid biopsy
    • 5.6.2.2 CRISPR
  • 5.6.3 ADJACENT TECHNOLOGIES
    • 5.6.3.1 Artificial intelligence (AI) and machine learning (ML)
    • 5.6.3.2 Sensors (wearable devices)
• 5.7 PRICING ANALYSIS
  • 5.7.1 INDICATIVE SELLING PRICE TREND OF ASSAY KITS, BY KEY PLAYER, 2022-2024
  • 5.7.2 INDICATIVE SELLING PRICE TREND OF BIOMARKER CONSUMABLES, BY REGION, 2024
• 5.8 PATENT ANALYSIS
  • 5.8.1 METHODOLOGY
  • 5.8.2 NUMBER OF PATENTS FILED, BY DOCUMENT TYPE, 2014-2025
• 5.9 ECOSYSTEM ANALYSIS
• 5.10 KEY CONFERENCES & EVENTS, 2025-2026
• 5.11 PORTER'S FIVE FORCES ANALYSIS
  • 5.11.1 INTENSITY OF COMPETITIVE RIVALRY
  • 5.11.2 BARGAINING POWER OF SUPPLIERS
  • 5.11.3 BARGAINING POWER OF BUYERS
  • 5.11.4 THREAT OF SUBSTITUTES
  • 5.11.5 THREAT OF NEW ENTRANTS
• 5.12 KEY STAKEHOLDERS & BUYING CRITERIA
  • 5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.12.2 BIOMARKERS MARKET: BUYING CRITERIA
• 5.13 INVESTMENT & FUNDING SCENARIO
• 5.14 TRADE DATA ANALYSIS
  • 5.14.1 IMPORT SCENARIO: HS CODE 382200, 2020-2024
  • 5.14.2 EXPORT SCENARIO: HS CODE 382200, 2020-2024
• 5.15 IMPACT OF AI/GENERATIVE AI ON BIOMARKERS MARKET
  • 5.15.1 INTRODUCTION
  • 5.15.2 USE CASES
  • 5.15.3 FUTURE OF AI IN BIOMARKER ECOSYSTEM
• 5.16 IMPACT OF 2025 US TARIFF ON BIOMARKERS MARKET
  • 5.16.1 KEY TARIFF RATES
  • 5.16.2 PRICE IMPACT ANALYSIS
  • 5.16.3 IMPACT ON COUNTRIES/REGIONS
    • 5.16.3.1 US
    • 5.16.3.2 Europe
    • 5.16.3.3 Asia Pacific
  • 5.16.4 IMPACT ON END-USE INDUSTRIES
    • 5.16.4.1 Pharmaceutical & biotech companies
    • 5.16.4.2 Hospitals & diagnostic laboratories
    • 5.16.4.3 Contract research organizations

6 BIOMARKERS MARKET, BY OFFERING

• 6.1 INTRODUCTION
• 6.2 CONSUMABLES
  • 6.2.1 ASSAY KITS
    • 6.2.1.1 Growing demand for assay kits in biomarker detection, quantification, and characterization to support growth
  • 6.2.2 REAGENTS & CHEMICALS
    • 6.2.2.1 Recurrent usage of reagents & chemicals in drug discovery and development to support demand
  • 6.2.3 OTHER CONSUMABLES
• 6.3 SERVICES
  • 6.3.1 GRADUAL TRANSITION FROM IN-HOUSE BIOMARKER TESTING TO OUTSOURCING SERVICES TO FUEL MARKET EXPANSION
• 6.4 SOFTWARE
  • 6.4.1 INCREASING ADOPTION OF BIOINFORMATICS TOOLS TO DRIVE MARKET GROWTH

7 BIOMARKERS MARKET, BY TYPE

• 7.1 INTRODUCTION
• 7.2 SAFETY BIOMARKERS
  • 7.2.1 WIDE APPLICATIONS OF SAFETY BIOMARKERS IN THERAPEUTIC AREAS TO BOOST MARKET GROWTH
• 7.3 EFFICACY BIOMARKERS
  • 7.3.1 PREDICTIVE BIOMARKERS
    • 7.3.1.1 Rising applications of biomarkers in personalized medicine to drive market
  • 7.3.2 SURROGATE BIOMARKERS
    • 7.3.2.1 Ability to serve as reliable indicator in place of clinical endpoints to support market growth
  • 7.3.3 PHARMACODYNAMIC BIOMARKERS
    • 7.3.3.1 Increasing utilization of pharmacodynamic biomarkers in biomarker and drug development to boost market
  • 7.3.4 PROGNOSTIC BIOMARKERS
    • 7.3.4.1 Increasing number of clinical trials to support growth of prognostic biomarkers
• 7.4 VALIDATION BIOMARKERS
  • 7.4.1 RISING RESEARCH FOR NEW DRUG DISCOVERY & DEVELOPMENT TO BOOST MARKET GROWTH

8 BIOMARKERS MARKET, BY RESEARCH AREA

• 8.1 INTRODUCTION
• 8.2 GENOMICS
  • 8.2.1 ADVANCEMENTS IN GENOMICS TECHNOLOGIES TO DRIVE SEGMENT GROWTH
• 8.3 PROTEOMICS
  • 8.3.1 GROWING PATIENT POPULATION WITH CHRONIC DISEASES TO DRIVE DEMAND
• 8.4 METABOLOMICS
  • 8.4.1 RISING INCIDENCE OF DIABETES AND OBESITY-RELATED CONDITIONS TO SUPPORT MARKET GROWTH
• 8.5 OTHER RESEARCH AREAS

9 BIOMARKERS MARKET, BY TECHNOLOGY

• 9.1 INTRODUCTION
• 9.2 IMMUNOASSAYS
  • 9.2.1 ELISA
    • 9.2.1.1 Extensive application of ELISA assays in clinical laboratories to support growth
  • 9.2.2 PROTEIN MICROARRAYS
    • 9.2.2.1 Quick and cost-effective nature of technology to support growth
  • 9.2.3 WESTERN BLOT
    • 9.2.3.1 Increasing investments in proteomics research to drive market
• 9.3 NEXT-GENERATION SEQUENCING (NGS)
  • 9.3.1 TECHNOLOGICAL ADVANCEMENTS IN NGS PLATFORMS TO SUPPORT GROWTH
• 9.4 POLYMERASE CHAIN REACTION (PCR)
  • 9.4.1 RAPID AND SENSITIVE DETECTION OF GENETIC BIOMARKERS TO DRIVE MARKET
• 9.5 MASS SPECTROMETRY
  • 9.5.1 INTEGRATION WITH OMICS TECHNOLOGIES TO DRIVE GROWTH
• 9.6 CHROMATOGRAPHY
  • 9.6.1 GROWING UTILIZATION IN PROTEOMICS RESEARCH TO SUPPORT MARKET GROWTH
• 9.7 OTHER TECHNOLOGIES

10 BIOMARKERS MARKET, BY DISEASE INDICATION

• 10.1 INTRODUCTION
• 10.2 CANCER
  • 10.2.1 INCREASING ADOPTION OF BIOMARKERS IN CANCER RESEARCH AND DIAGNOSIS TO DRIVE MARKET
• 10.3 INFECTIOUS DISEASES
  • 10.3.1 INCREASING RESEARCH AND GROWING FUNDING TO IDENTIFY BIOMARKERS FOR INFECTIOUS DISEASES TO DRIVE DEMAND
• 10.4 IMMUNOLOGICAL DISORDERS
  • 10.4.1 RISING ADOPTION OF ASSAYS FOR AUTOIMMUNE DISEASE DETECTION TO DRIVE MARKET
• 10.5 NEUROLOGICAL DISORDERS
  • 10.5.1 WIDE USE OF BIOMARKERS IN DIAGNOSIS AND PRECISION MEDICINE OF NEUROLOGICAL DISORDERS TO SUPPORT GROWTH
• 10.6 CARDIOVASCULAR DISORDERS
  • 10.6.1 GROWING PREVALENCE OF CVD TO INCREASE DEMAND FOR CARDIAC BIOMARKERS
• 10.7 OTHER DISEASE INDICATIONS

11 BIOMARKERS MARKET, BY APPLICATION

• 11.1 INTRODUCTION
• 11.2 CLINICAL DIAGNOSTICS
  • 11.2.1 GROWING FOCUS ON EARLY DISEASE DETECTION AND DIAGNOSIS TO SUPPORT DEMAND
• 11.3 DRUG DISCOVERY & DEVELOPMENT
  • 11.3.1 INCREASING UTILIZATION OF BIOMARKERS IN DRUG DEVELOPMENT TO SUPPORT GROWTH
• 11.4 PERSONALIZED MEDICINE
  • 11.4.1 GROWING PREFERENCE FOR PRECISION THERAPEUTICS TO SUPPORT DEMAND
• 11.5 CLINICAL RESEARCH
  • 11.5.1 GROWING NUMBER OF CLINICAL TRIALS TO PROPEL MARKET
• 11.6 OTHER APPLICATIONS

12 BIOMARKERS MARKET, BY END USER

• 12.1 INTRODUCTION
• 12.2 PHARMACEUTICAL & BIOTECHNOLOGIES COMPANIES
  • 12.2.1 GROWING MARKET STRATEGIES BY KEY PLAYERS TO SUPPORT MARKET GROWTH
• 12.3 HOSPITALS & DIAGNOSTIC LABORATORIES
  • 12.3.1 VITAL ROLE OF BIOMARKERS AS BIOLOGICAL INDICATORS IN DIAGNOSIS OF DISEASES TO FUEL MARKET GROWTH
• 12.4 ACADEMIC & RESEARCH INSTITUTES
  • 12.4.1 INCREASING FUNDING ACTIVITIES TO DRIVE MARKET
• 12.5 OTHER END USERS

13 BIOMARKERS MARKET, BY REGION

• 13.1 INTRODUCTION
• 13.2 NORTH AMERICA
  • 13.2.1 MACROECONOMIC OUTLOOK OF NORTH AMERICA
  • 13.2.2 US
    • 13.2.2.1 Rising focus on biopharma research to support growth
  • 13.2.3 CANADA
    • 13.2.3.1 Increasing incidence of cancer to drive biomarkers market growth
• 13.3 EUROPE
  • 13.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 13.3.2 GERMANY
    • 13.3.2.1 Growth in biopharmaceutical R&D activities to propel growth
  • 13.3.3 UK
    • 13.3.3.1 Government funding and strategic collaborations with biotech firms to boost adoption of biomarkers
  • 13.3.4 FRANCE
    • 13.3.4.1 Increasing government investment for proteomics & genomics research to drive growth
  • 13.3.5 ITALY
    • 13.3.5.1 Increasing developments in life science research to fuel growth
  • 13.3.6 SPAIN
    • 13.3.6.1 R&D initiatives for personalized medicine to support market growth
  • 13.3.7 REST OF EUROPE
• 13.4 ASIA PACIFIC
  • 13.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 13.4.2 CHINA
    • 13.4.2.1 Rising incidence of CVD to propel market
  • 13.4.3 JAPAN
    • 13.4.3.1 Strong regulatory guidelines for drug discovery & development to support market growth
  • 13.4.4 INDIA
    • 13.4.4.1 Favorable scenario for FDI and increasing number of clinical trials to propel market
  • 13.4.5 SOUTH KOREA
    • 13.4.5.1 Increasing innovations in NGS technologies to support market growth
  • 13.4.6 AUSTRALIA
    • 13.4.6.1 Increasing demand for diagnostic solutions to propel market
  • 13.4.7 REST OF ASIA PACIFIC
• 13.5 LATIN AMERICA
  • 13.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 13.5.2 BRAZIL
    • 13.5.2.1 Increased government investments in pharmaceutical R&D to drive market
  • 13.5.3 MEXICO
    • 13.5.3.1 Rising demand for chronic disease treatment to support market growth
  • 13.5.4 REST OF LATIN AMERICA
• 13.6 MIDDLE EAST
  • 13.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
  • 13.6.2 GCC COUNTRIES
  • 13.6.3 SAUDI ARABIA
    • 13.6.3.1 Growing healthcare expenditure to boost market growth
  • 13.6.4 UAE
    • 13.6.4.1 Increasing collaborative efforts for pharmaceutical R&D to drive growth
  • 13.6.5 REST OF GCC COUNTRIES
    • 13.6.5.1 Other GCC countries include Bahrain, Kuwait, Oman, and Qatar.
  • 13.6.6 REST OF MIDDLE EAST
    • 13.6.6.1 The Rest of the Middle East includes Egypt, Turkey, Iran, and Iraq.
• 13.7 AFRICA
  • 13.7.1 INCREASING DEMAND FOR DRUG DISCOVERY & DEVELOPMENT TO PROPEL MARKET
  • 13.7.2 MACROECONOMIC OUTLOOK FOR AFRICA

14 COMPETITIVE LANDSCAPE

• 14.1 INTRODUCTION
• 14.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 14.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN BIOMARKERS MARKET
• 14.3 REVENUE ANALYSIS, 2022-2024
• 14.4 MARKET SHARE ANALYSIS, 2024
• 14.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  • 14.5.1 STARS
  • 14.5.2 EMERGING LEADERS
  • 14.5.3 PERVASIVE PLAYERS
  • 14.5.4 PARTICIPANTS
  • 14.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
    • 14.5.5.1 Company footprint
    • 14.5.5.2 Region footprint
    • 14.5.5.3 Offering footprint
    • 14.5.5.4 Technology footprint
    • 14.5.5.5 Application footprint
• 14.6 COMPANY EVALUATION MATRIX: START-UPS/SMES, 2024
  • 14.6.1 PROGRESSIVE COMPANIES
  • 14.6.2 RESPONSIVE COMPANIES
  • 14.6.3 DYNAMIC COMPANIES
  • 14.6.4 STARTING BLOCKS
  • 14.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
    • 14.6.5.1 Detailed list of key startups/SMEs
    • 14.6.5.2 Competitive benchmarking of key startups/SMEs
• 14.7 COMPANY VALUATION & FINANCIAL METRICS
  • 14.7.1 VALUATION OF KEY PLAYERS
  • 14.7.2 FINANCIAL METRICS OF KEY PLAYERS
• 14.8 BRAND/PRODUCT COMPARATIVE ANALYSIS
  • 14.8.1 BIOMARKER MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS OF BIOMARKER-BASED ASSAYS
• 14.9 COMPETITIVE SCENARIO
  • 14.9.1 PRODUCT LAUNCHES & APPROVALS
  • 14.9.2 DEALS
  • 14.9.3 EXPANSIONS

15 COMPANY PROFILES

• 15.1 KEY PLAYERS
  • 15.1.1 THERMO FISHER SCIENTIFIC INC.
    • 15.1.1.1 Business overview
    • 15.1.1.2 Products & services offered
    • 15.1.1.3 Recent developments
      • 15.1.1.3.1 Product launches & approvals
      • 15.1.1.3.2 Deals
      • 15.1.1.3.3 Expansions
    • 15.1.1.4 MnM view
      • 15.1.1.4.1 Right to win
      • 15.1.1.4.2 Strategic choices
      • 15.1.1.4.3 Weaknesses & competitive threats
  • 15.1.2 MERCK KGAA
    • 15.1.2.1 Business overview
    • 15.1.2.2 Products & services offered
    • 15.1.2.3 Recent developments
      • 15.1.2.3.1 Deals
      • 15.1.2.3.2 Expansions
    • 15.1.2.4 MnM view
      • 15.1.2.4.1 Right to win
      • 15.1.2.4.2 Strategic choices
      • 15.1.2.4.3 Weaknesses & competitive threats
  • 15.1.3 F. HOFFMANN-LA ROCHE LTD.
    • 15.1.3.1 Business overview
    • 15.1.3.2 Products & services offered
    • 15.1.3.3 Recent developments
      • 15.1.3.3.1 Product launches & approvals
      • 15.1.3.3.2 Deals
  • 15.1.4 QIAGEN
    • 15.1.4.1 Business overview
    • 15.1.4.2 Products & services offered
    • 15.1.4.3 Recent developments
      • 15.1.4.3.1 Product launches & approvals
      • 15.1.4.3.2 Deals
      • 15.1.4.3.3 Expansions
  • 15.1.5 ABBOTT
    • 15.1.5.1 Business overview
    • 15.1.5.2 Products & services offered
    • 15.1.5.3 Recent developments
      • 15.1.5.3.1 Product launches & approvals
      • 15.1.5.3.2 Deals
  • 15.1.6 AGILENT TECHNOLOGIES, INC.
    • 15.1.6.1 Business overview
    • 15.1.6.2 Products & services offered
    • 15.1.6.3 Recent developments
      • 15.1.6.3.1 Product launches & approvals
      • 15.1.6.3.2 Deals
  • 15.1.7 REVVITY INC.
    • 15.1.7.1 Business overview
    • 15.1.7.2 Products & services offered
  • 15.1.8 CHARLES RIVER LABORATORIES
    • 15.1.8.1 Business overview
    • 15.1.8.2 Products & services offered
    • 15.1.8.3 Recent developments
      • 15.1.8.3.1 Deals
  • 15.1.9 BIO-RAD LABORATORIES, INC.
    • 15.1.9.1 Business overview
    • 15.1.9.2 Products & services offered
    • 15.1.9.3 Recent developments
      • 15.1.9.3.1 Product launches
      • 15.1.9.3.2 Deals
  • 15.1.10 EUROFINS SCIENTIFIC
    • 15.1.10.1 Business overview
    • 15.1.10.2 Products & services offered
    • 15.1.10.3 Recent developments
      • 15.1.10.3.1 Deals
  • 15.1.11 BIOMERIEUX
    • 15.1.11.1 Business overview
    • 15.1.11.2 Products & services offered
    • 15.1.11.3 Recent developments
      • 15.1.11.3.1 Product launches & approvals
      • 15.1.11.3.2 Deals
  • 15.1.12 ILLUMINA, INC.
    • 15.1.12.1 Business overview
    • 15.1.12.2 Products & services offered
    • 15.1.12.3 Recent developments
      • 15.1.12.3.1 Product launches & approvals
      • 15.1.12.3.2 Deals
  • 15.1.13 JSR CORPORATION
    • 15.1.13.1 Business overview
    • 15.1.13.2 Products & services offered
    • 15.1.13.3 Recent developments
      • 15.1.13.3.1 Deals
  • 15.1.14 GUARDANT HEALTH
    • 15.1.14.1 Business overview
    • 15.1.14.2 Products & services offered
    • 15.1.14.3 Recent developments
      • 15.1.14.3.1 Product launches & approvals
      • 15.1.14.3.2 Deals
  • 15.1.15 LABCORP
    • 15.1.15.1 Business overview
    • 15.1.15.2 Products & services offered
    • 15.1.15.3 Recent developments
      • 15.1.15.3.1 Product launches
  • 15.1.16 QUANTERIX
    • 15.1.16.1 Business overview
    • 15.1.16.2 Products & services offered
    • 15.1.16.3 Recent developments
      • 15.1.16.3.1 Product launches
      • 15.1.16.3.2 Deals
  • 15.1.17 MESO SCALE DIAGNOSTICS, LLC
    • 15.1.17.1 Business overview
    • 15.1.17.2 Products & services offered
• 15.2 OTHER PLAYERS
  • 15.2.1 CELERION
  • 15.2.2 STANDARD BIOTOOLS
  • 15.2.3 SEBIA
  • 15.2.4 BIOAGILYTIX LABS
  • 15.2.5 STRESSMARQ BIOSCIENCES INC.
  • 15.2.6 NORTHEAST BIOANALYTICAL LABORATORIES LLC
  • 15.2.7 SIGNOSIS
  • 15.2.8 SERIMMUNE
  • 15.2.9 THERAINDX LIFESCIENCES PVT. LTD.
  • 15.2.10 SYNEXA LIFE SCIENCES BV
  • 15.2.11 DIATECH PHARMACOGENETICS
  • 15.2.12 SINGULEX, INC.
  • 15.2.13 R-BIOPHARM AG

16 APPENDIX

• 16.1 DISCUSSION GUIDE
• 16.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 16.3 CUSTOMIZATION OPTIONS
• 16.4 RELATED REPORTS
• 16.5 AUTHOR DETAILS